drugset / Trial / NCT07541287
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NaSingle-groupOpen-labelTreatment
Summary
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Timeline
- Start
- 2026-05-19
- Primary completion
- 2029-01
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JADE101 | Unknown | — | Subcutaneous |